Skip to content
Vesalius Therapeutics

Our Leadership

Ben Munoz, PhD
Ben Munoz, PhD
SVP, Head of Drug Discovery
John Mendlein, PhD
John Mendlein, PhD

Executive Chairman and Interim CEO

Board of Directors

Doug Cole, MD
Doug Cole, MD

Managing Partner, Flagship Pioneering
Founder Vesalius

John Mendlein, PhD
John Mendlein, PhD

Executive Partner, Flagship Pioneering

Scientific Advisory Board

  • Lee Rubin

    Professor of Stem Cell and Regenerative Biology, Harvard University, and Co-Director, Neuroscience Program, Harvard Stem Cell Institute

  • Paola Arlotta

    Chair, Department of Stem Cell & Regenerative Biology, Harvard University

  • Percy Carter

    Chief Scientific Officer, Blueprint Medicines

  • John A. Todd

    Director, Wellcome Centre for Human Genetics, University of Oxford

  • Wendy Chung

    Chief of Pediatrics, Boston Children's Hospital

  • Tanya Fischer

    Chief Development Officer and Head of Translational Medicine, Biohaven

  • Justin Ichida

    Associate Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California

  • 03/07/2024

    Vesalius Therapeutics Announces Leadership Transition

    Vesalius Therapeutics today announced that John Mendlein, Ph.D., will become the company’s Executive Chairman, and interim Chief Executive Officer.

    Read More
  • 08/01/2022

    Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs

    Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.

    Read More
  • 03/01/2022

    Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness

    Flagship Pioneering today unveiled Vesalius Therapeutics, a company focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness. Flagship initially committed $75 million to support the development of Vesalius’ platform and initial pipeline of new medicines.

    Read More